MeSH term
Frequency | Condition_Probility | Aged | 3 | 0.0 |
Base Sequence | 15 | 0.0 |
Blotting, Northern | 2 | 0.0 |
Comparative Study | 8 | 0.0 |
Dose-Response Relationship, Drug | 5 | 0.0 |
Female | 14 | 0.0 |
Gene Expression Regulation | 5 | 0.0 |
Humans | 78 | 0.0 |
Male | 9 | 0.0 |
Molecular Sequence Data | 19 | 0.0 |
Polymerase Chain Reaction | 4 | 0.0 |
Transcription, Genetic | 8 | 0.0 |
Blotting, Western | 9 | 0.0 |
Cell Line | 18 | 0.0 |
DNA/metabolism | 2 | 0.0 |
DNA-Binding Proteins/*metabolism | 4 | 0.0 |
Proto-Oncogene Proteins c-fos/*metabolism | 4 | 11.0 |
Proto-Oncogene Proteins c-jun/*metabolism | 4 | 5.0 |
Research Support, Non-U.S. Gov't | 57 | 0.0 |
Transcription Factor AP-1/*metabolism | 10 | 6.0 |
Transcription Factors/*metabolism | 5 | 0.0 |
Animals | 38 | 0.0 |
COS Cells | 2 | 0.0 |
Cercopithecus aethiops | 2 | 0.0 |
DNA Primers | 7 | 0.0 |
*Gene Expression Regulation | 5 | 0.0 |
Genes, Reporter | 3 | 0.0 |
Genes, fos/drug effects | 4 | 17.0 |
Genes, jun/drug effects | 3 | 33.0 |
Immediate-Early Proteins/genetics | 2 | 4.0 |
Luciferases/genetics | 2 | 0.0 |
Mice | 19 | 0.0 |
Protein-Tyrosine Kinase/metabolism | 2 | 0.0 |
Tetradecanoylphorbol Acetate/pharmacology | 4 | 0.0 |
Transfection | 10 | 0.0 |
Tumor Cells, Cultured | 13 | 0.0 |
Cells, Cultured | 12 | 0.0 |
Gene Expression Regulation/*physiology | 2 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 17 | 0.0 |
Transcription Factor AP-1/*physiology | 2 | 5.0 |
Mitogen-Activated Protein Kinases/metabolism | 3 | 0.0 |
Trans-Activators/*metabolism | 3 | 0.0 |
DNA-Binding Proteins/metabolism | 6 | 0.0 |
*Nuclear Proteins | 3 | 0.0 |
*Promoter Regions (Genetics) | 4 | 0.0 |
Proto-Oncogene Proteins c-fos/metabolism | 5 | 4.0 |
Proto-Oncogene Proteins c-jun/metabolism | 6 | 4.0 |
Transcription Factor AP-1/metabolism | 9 | 3.0 |
Gene Expression | 4 | 0.0 |
Middle Aged | 7 | 0.0 |
Transcription Factor AP-1/*biosynthesis | 2 | 33.0 |
*Gene Expression Regulation, Neoplastic | 3 | 0.0 |
Genetic Vectors | 2 | 0.0 |
Immunohistochemistry | 6 | 0.0 |
Phosphorylation | 5 | 0.0 |
Signal Transduction/physiology | 3 | 0.0 |
Stimulation, Chemical | 2 | 0.0 |
Transcription Factor AP-1/genetics/*metabolism | 4 | 15.0 |
Cell Line, Tumor | 2 | 0.0 |
DNA-Binding Proteins/genetics/metabolism | 2 | 0.0 |
Promoter Regions (Genetics) | 4 | 0.0 |
Proto-Oncogene Proteins c-jun/genetics/metabolism | 2 | 5.0 |
Transcription Factors/genetics/metabolism | 3 | 0.0 |
Kinetics | 8 | 0.0 |
RNA, Messenger/metabolism | 3 | 0.0 |
Proto-Oncogene Proteins c-fos/analysis | 2 | 16.0 |
Receptors, Progesterone/*analysis | 2 | 0.0 |
Gene Expression/drug effects | 3 | 0.0 |
Proto-Oncogene Proteins c-fos/genetics | 2 | 3.0 |
RNA, Messenger/analysis | 4 | 0.0 |
Time Factors | 4 | 0.0 |
Transcription Factor AP-1/*genetics | 2 | 10.0 |
DNA-Binding Proteins/genetics | 3 | 0.0 |
Epithelial Cells/drug effects/metabolism | 2 | 2.0 |
Oligopeptides/*pharmacology | 2 | 2.0 |
Pyrrolidonecarboxylic Acid/analogs & derivatives | 2 | 8.0 |
Transcription Factors/genetics | 4 | 0.0 |
*Cell Transformation, Neoplastic | 2 | 0.0 |
Apoptosis/*drug effects | 2 | 0.0 |
Cell Division/drug effects | 3 | 0.0 |
Protein Binding | 5 | 0.0 |
*Proto-Oncogene Proteins c-fos | 7 | 100.0 |
Trans-Activation (Genetics)/drug effects | 2 | 0.0 |
Breast Neoplasms/*metabolism/pathology | 2 | 1.0 |
Hela Cells | 5 | 0.0 |
Bacterial Proteins/metabolism | 2 | 3.0 |
Culture Media, Serum-Free | 2 | 0.0 |
Enzyme Activation | 2 | 0.0 |
Enzyme Inhibitors/pharmacology | 4 | 0.0 |
Genes, Dominant | 2 | 0.0 |
Mutagenesis, Site-Directed | 2 | 0.0 |
Rats | 8 | 0.0 |
Signal Transduction | 3 | 0.0 |
Transcription Factors/metabolism | 3 | 0.0 |
Binding Sites | 6 | 0.0 |
Dimerization | 4 | 0.0 |
Pregnancy | 2 | 0.0 |
Recombinant Fusion Proteins/metabolism | 4 | 0.0 |
Phenotype | 3 | 0.0 |
Proto-Oncogene Proteins c-fos/*analysis | 2 | 28.0 |
Proto-Oncogene Proteins c-jun/*analysis | 2 | 66.0 |
Adult | 3 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 2 | 0.0 |
Fibroblasts/drug effects/metabolism | 2 | 1.0 |
Proto-Oncogene Proteins c-fos/genetics/*metabolism | 4 | 16.0 |
Transcription, Genetic/*drug effects | 4 | 1.0 |
Genes, fos/genetics | 2 | 4.0 |
Genes, jun/genetics | 2 | 12.0 |
RNA, Messenger/genetics/metabolism | 2 | 0.0 |
DNA, Complementary/genetics | 3 | 0.0 |
Amino Acid Sequence | 7 | 0.0 |
*CCAAT-Enhancer-Binding Proteins | 2 | 1.0 |
Conserved Sequence | 3 | 0.0 |
*Saccharomyces cerevisiae Proteins | 2 | 0.0 |
Trans-Activation (Genetics) | 3 | 0.0 |
Okadaic Acid/*pharmacology | 2 | 20.0 |
DNA-Binding Proteins/biosynthesis/genetics | 2 | 2.0 |
Gene Expression Regulation/drug effects | 2 | 0.0 |
In Situ Hybridization | 3 | 0.0 |
Proto-Oncogene Proteins c-fos/*genetics | 2 | 8.0 |
Transformation, Genetic | 2 | 1.0 |
Ca(2+)-Calmodulin Dependent Protein Kinase/physiology | 2 | 5.0 |
Proto-Oncogenes/genetics | 2 | 6.0 |
RNA, Messenger/biosynthesis | 4 | 0.0 |
Cycloheximide/pharmacology | 2 | 0.0 |
Protein Biosynthesis | 2 | 0.0 |
Trans-Activation (Genetics)/*physiology | 2 | 1.0 |
Calcium/physiology | 2 | 0.0 |
Carbachol/pharmacology | 2 | 2.0 |
Genes, fos/*genetics | 3 | 15.0 |
Genes, jun/*genetics | 2 | 28.0 |
Neuroblastoma | 2 | 1.0 |
RNA, Messenger/genetics | 5 | 0.0 |
*Genes, fos | 2 | 3.0 |
Multigene Family | 2 | 0.0 |
Proto-Oncogene Proteins c-fos/*biosynthesis | 3 | 21.0 |
Proto-Oncogene Proteins c-jun/*biosynthesis | 3 | 33.0 |
Mutation | 3 | 0.0 |
Nuclear Proteins/metabolism | 2 | 0.0 |
Drug Resistance, Microbial/genetics | 2 | 2.0 |
Fosfomycin/*pharmacology | 2 | 66.0 |
*Genes, Bacterial | 2 | 2.0 |
In Vitro | 3 | 0.0 |
Microbial Sensitivity Tests | 2 | 0.0 |
Nucleic Acid Hybridization | 2 | 0.0 |
Sequence Analysis, DNA | 2 | 0.0 |
Rabbits | 2 | 0.0 |
Structure-Activity Relationship | 2 | 0.0 |
*Transcription, Genetic | 3 | 0.0 |
DNA Primers/chemistry | 2 | 0.0 |
Lymphocyte Activation/*physiology | 2 | 2.0 |
Gene Expression Regulation, Neoplastic/*drug effects | 2 | 0.0 |
3T3 Cells | 2 | 0.0 |
Anticarcinogenic Agents/*pharmacology | 2 | 2.0 |
Proto-Oncogenes/drug effects | 2 | 22.0 |
Cell Differentiation | 2 | 0.0 |
Oligonucleotide Probes | 2 | 0.0 |
Gene Expression Profiling | 2 | 0.0 |
Blood Physiology | 2 | 2.0 |
Gene Expression Regulation/*drug effects | 2 | 0.0 |
Genes, jun | 3 | 3.0 |
Proto-Oncogene Proteins c-jun/*physiology | 2 | 9.0 |
Transcription, Genetic/drug effects | 2 | 0.0 |
*Transformation, Genetic | 2 | 8.0 |
Growth Substances/*pharmacology | 2 | 0.0 |
Platelet-Derived Growth Factor/pharmacology | 2 | 1.0 |
Alternative Splicing | 2 | 0.0 |
Cloning, Molecular | 2 | 0.0 |
Restriction Mapping | 2 | 0.0 |
Transcription Factors/*genetics | 2 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 2 | 0.0 |
Regulatory Sequences, Nucleic Acid | 2 | 0.0 |
Proto-Oncogene Proteins c-fos | 3 | 5.0 |
Proto-Oncogene Proteins c-jun | 2 | 4.0 |
Oligonucleotide Array Sequence Analysis | 2 | 0.0 |
Evolution | 2 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 2 | 0.0 |